Format

Send to:

Choose Destination
See comment in PubMed Commons below
Lancet. 2008 Oct 18;372(9647):1394-402. doi: 10.1016/S0140-6736(08)61412-9. Epub 2008 Sep 25.

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.

Collaborators (384)

Fox Y, George M, Svensson A, Hainer J, Warnold I, Agardh CD, Bonnici F, Charbonnel B, Cooper M, Dedov I, Gardiner R, Gomis R, Ilkova H, Katsilambros N, Kerenyi Z, Martin S, Massin P, Pirags V, Porta M, Raz I, Rusavy Z, Schernthaner G, Shestakova M, Sjølie AK, Strojek K, Olofsson B, Malm A, Wissmar J, Brayshaw N, Wedel H, Wilhelmsen L, Bird A, Wedel H, Warnold I, Price G, Adler-Ekholm E, Aldington S, Dahl M, Deveney A, Karlsten E, Levins P, Lipinski H, Prenter C, Walkey H, Walters N, Cooper M, Chen R, Colman P, Davoren P, Donnelly T, d'Emden M, Jerums G, O'Brien R, Phillips P, Prins J, Roberts A, Watts G, Wilson D, Yue D, Zoungas S, Schernthaner G, Luger A, Pilger E, Prager R, Waldhäusl WK, Weitgasser R, Keymeulen B, Van Gaal L, Christov V, Hristozov K, Koeva L, Markova A, Protich M, Slavcheva A, Tankova T, Toneva A, Veleva N, Zaharieva M, Gardiner R, Babin S, Belanger A, Godin C, Joyce C, Keely E, Leiter L, Lochnan H, McManus R, Miller D, Monchesky T, Pylypchuk G, Ross S, Siegel I, Tobe S, Ur E, Woo V, Toth E, Kovacevic D, Profozic V, Rusavy Z, Andel M, Boucek P, Chmura P, Gregorova A, Havelkova J, Karasova J, Musil F, Olsovsky J, Patek F, Plesnikova B, Pospisilova Y, Racicka E, Zawadova J, Sjølie AK, Bek T, Hermansen K, Lervang HH, Parving HH, Rossing P, Past M, Tupits H, Podar T, Chabonnel B, Massin P, Anton B, Charpentier P, Grimaldi A, Guillausseau PJ, Kerlan V, Marechaud J, Marre M, Nocent P, Penformis A, Rodier M, Ruiz JP, Slama G, Combes ME, Gagunashvili N, Kurashvili R, Metreveli D, Martin S, Allolio B, Anderten H, Badenhoop K, Busch K, Dreyer M, Etzrodt H, Frank M, Pfeiffer A, von Reis EO, Schneider M, Schäffler A, Stuermer W, Usadel KH, Katsilambros N, Karamanos B, Melidonis A, Mygdalis I, Noutsou M, Pagalos E, Papadam A, Pappas A, Pappas S, Phenekos K, Piaditis G, Kerényi Z, Baranyai M, Bölcsvölgyi T, Dömötör E, Faludi P, Fövényi J, Koranyi L, Szöcs A, Tamás G, Tárko M, Vándorfi G, Ferriss B, McKenna J, O'Shea D, O'Sullivan S, Raz I, Adawi F, Arcavi L, Cohen J, Cohen O, Dicker D, Guttmann H, Harman-Boehm I, Herskovits T, Jaffe A, Karnieli E, Loewinger Z, Luboshitzky R, Nabriski D, Oren S, Phillip M, Ravid M, Rubinstein A, Shehadeh N, Slezak L, Stern E, Wainstein J, Yerushalmi Y, Porta M, Corgiat-Mansin L, Crepaldi G, Galluzzo A, Ghirlanda G, Invitti C, Noacco C, Piatti P, Realdi G, Saccardi F, Santeusanio F, Viviani GL, Pirags V, Jegere B, Laganovska G, Rasa I, Vinsteine I, Danileviclus J, Norkus A, Zalinkevicius R, Michel G, Wirion R, Drury P, Dunn P, Scott R, Toomath R, Strojek K, Bandurska-Stankiewicz E, Idzior-Walus B, Karnafel W, Koziol M, Krzyzagorska E, Lopatynski J, Markiewicz K, Mikolajczyk-Swatko A, Polaszwska-Muszynska M, Pynka S, Semetkowska-Jurkiewicz E, Gardete L, Gomes MJ, Sa A, Angelescu ML, Graur M, Mota M, Suciu GC, Tirgoviste CI, Veresiu AI, Dedoc I, Shestakova M, Ametov A, Bondar I, Bova E, Chizhova O, Demidova I, Dogadin S, Elpatova V, Gasparyan E, Ipatko I, Ivanova T, Jakovlevna BF, Karpova I, Khintal T, Kholopova E, Khrustalev O, Kolenko O, Korshennikov V, Kravez E, Krivolapova T, Kudriashova N, Melnichenkov G, Milovanova T, Mkrtumyan A, Morozova A, Nikiforova O, Ponomareva A, Rechkova E, Rodionova T, Shustov S, Smimova E, Suplotova L, Verbovaya N, Vladislavovich S, Vorokhobina N, Yakusevich V, Zarutskaya L, Zudaev V, Zykova T, Bonnici F, Amod A, van den Berg E, Brijkumar J, Chidi G, Distiller L, Doubell A, Fraser P, Jacovides A, Kelbe D, Kaplan H, Kok J, Lourens W, Mayet L, Moore R, Murray S, Naidoo V, Naiker P, Nortje H, Omar MA, Parker G, Philotheou A, Polakow ES, Postma A, Ramdass A, Randeree H, Robertson L, Sarvan MI, Smuts MS, Solomon E, Wellman H, Wing J, Gomis R, Albero R, Baldrich AG, Barberia Layana JJ, Peralta FG, González Albarrán O, Louis F, Sarda AN, Pinon-Selles F, Agardh CD, Adamson U, Agardh E, Alvarsson M, Lager I, Lindmark S, Nilsson A, Norberg B, Svensson M, Ilkova H, Aral Y, Ayvaz G, Baskal N, Dagdelen S, Erdogan G, Kaya A, Tanyeri F, Yilmaz C, Bilous R, Akintewe T, Anderson J, Beer S, Borthwick L, Boulton A, Collier A, Darko D, Doig J, Evans P, Gibby O, Greenwood R, Hart P, Hopkins D, Hyer S, Issa B, Jones G, Lawrence I, Leese G, Lorrains J, Martin U, Nagi D, O'Hare JP, Page S, Patel V, Robertson D, Sampson M, Sandeman D, Walford S, Walker J, Webber J, Wiles P, Winocour P, Tesfaye S, Tooke J, Yang Y.

Abstract

BACKGROUND:

Results of previous studies suggest that renin-angiotensin system blockers might reduce the burden of diabetic retinopathy. We therefore designed the DIabetic REtinopathy Candesartan Trials (DIRECT) Programme to assess whether candesartan could reduce the incidence and progression of retinopathy in type 1 diabetes.

METHODS:

Two randomised, double-blind, parallel-design, placebo-controlled trials were done in 309 centres worldwide. Participants with normotensive, normoalbuminuric type 1 diabetes without retinopathy were recruited to the DIRECT-Prevent 1 trial and those with existing retinopathy were recruited to DIRECT-Protect 1, and were assigned to candesartan 16 mg once a day or matching placebo. After 1 month, the dose was doubled to 32 mg. Investigators and participants were unaware of the treatment allocation status. The primary endpoints were incidence and progression of retinopathy and were defined as at least a two-step and at least a three-step increase on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale, respectively. These trials are registered with ClinicalTrials.gov, numbers NCT00252733 for DIRECT-Prevent 1 and NCT00252720 for DIRECT-Protect 1.

FINDINGS:

1421 participants (aged 18-50 years) were randomly assigned to candesartan (n=711) or to placebo (n=710) in DIRECT-Prevent 1, and 1905 (aged 18-55 years) to candesartan (n=951) or to placebo (n=954) in DIRECT-Protect 1. Incidence of retinopathy was seen in 178 (25%) participants in the candesartan group versus 217 (31%) in the placebo group. Progression of retinopathy occurred in 127 (13%) participants in the candesartan group versus 124 (13%) in the placebo group. Hazard ratio (HR for candesartan vs placebo) was 0.82 (95% CI 0.67-1.00, p=0.0508) for incidence of retinopathy and 1.02 (0.80-1.31, p=0.85) for progression of retinopathy. The post-hoc outcome of at least a three-step increase for incidence yielded an HR of 0.65 (0.48-0.87, p=0.0034), which was attenuated but still significant after adjustment for baseline characteristics (0.71, 0.53-0.95, p=0.046). Final ETDRS level was more likely to have improved with candesartan treatment in both DIRECT-Prevent 1 (odds 1.16, 95% CI 1.05-1.30, p=0.0048) and DIRECT-Protect 1 (1.12, 95% CI 1.01-1.25, p=0.0264). Adverse events did not differ between the treatment groups.

INTERPRETATION:

Although candesartan reduces the incidence of retinopathy, we did not see a beneficial effect on retinopathy progression.

PMID:
18823656
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk